ArticleAmerican heart journal plus : cardiology research and practice2026
Phenotypic age acceleration and all-cause and cardiovascular mortality among U.S. adults at risk for heart failure.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the associations of phenotypic age acceleration (PAA) with all-cause and cardiovascular mortality among U.S. adults at risk for heart failure. Methods: We analyzed 19,665 participants aged ≥20 years at risk for heart failure from the National Health and Nutrition Examination Survey (NHANES) 1999-2010 and 2015-2018. PAA was defined as the residual from regressing phenotypic age on chronological age. Kaplan-Meier analysis, weighted Cox regression, Fine-Gray competing-risk models, and restricted cubic spline analyses were used to evaluate these associations. Results: Compared with the lowest quartile, participants in the highest quartile of PAA had higher risks of all-cause mortality (HR, 2.63; 95% CI, 2.31-2.98) and cardiovascular mortality (HR, 2.55; 95% CI, 2.00-3.25). Restricted cubic spline analysis showed a nonlinear association between PAA and all-cause mortality (P for nonlinearity = 0.005), with a threshold at PAA = -8.26, whereas the association with cardiovascular mortality was linear (P for nonlinearity = 0.881). In competing-risk analysis, the highest PAA quartile remained significantly associated with increased cardiovascular mortality (SHR, 1.39; 95% CI, 1.15-1.68). Conclusion: Higher PAA was significantly associated with increased risks of all-cause and cardiovascular mortality among adults at risk for heart failure, suggesting that PAA may be a potential marker of mortality risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.